Trial · NCT07890272
Hyaluronic Acid Gel After Impacted Mandibular Third Molar Surgery
NCT07890272, Not applicable, Completed, University of Medicine and Pharmacy at Ho Chi Minh City
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hyaluronic Acid Gel After Impacted Mandibular Third Molar Surgery. Trials, record NCT07890272. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890272
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hyaluronic Acid Gel After Impacted Mandibular Third Molar Surgery
- NCT number
- NCT07890272
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 25 participants, actual
- Lead sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
- Conditions
- Impacted Mandibular Third Molar Extraction
- Interventions
- 0.2% Hyaluronic Acid Gel
- First posted
- 2026-10-22
- Last updated
- 2026-11-09
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Postoperative pain | Postoperative days 1, 3, and 7 after each surgical procedure. | Participants rate pain on a six-level descriptive scale ranging from 0 to 5: 0, no pain; 1, pain not noticed unless attended to; 2, pain noticed while concentrating on other tasks; 3, marked discomfort but able to continue daily activities; 4, pain requiring cessation of all activities; and 5, pain requiring cessation of all activities and bed rest. Higher scores indicate greater pain severity. Assessments are completed in the evening. |
| Primary | Subjective swelling | Postoperative days 1, 3, and 7 after each surgical procedure. | Participants rate perceived swelling on a six-level descriptive scale ranging from 0 (no swelling) to 5 (marked swelling with limited mouth opening). Intermediate categories reflect the degree of interference with chewing and swallowing. Higher scores indicate greater perceived swelling. Assessments are completed in the evening |
| Primary | Maximum Mouth Opening | Preoperatively and on postoperative days 3 and 7 after each surgical procedure. | Maximum mouth opening is measured in millimeters using a digital caliper between the incisal edges of the same upper and lower central incisors. Postoperative measurements are compared with the preoperative baseline for each surgical procedure and are also expressed as a percentage of baseline. Lower postoperative values indicate greater limitation of mouth opening. |
| Secondary | Objective swelling | Baseline before each surgical procedure and postoperative days 3 and 7. | Facial swelling is assessed using three distances measured with a flexible tape: segment A, tragus to soft-tissue pogonion; segment B, tragus to labial commissure; and segment C, lateral canthus to gonial angle. Measurements are obtained with the teeth in occlusion, rounded to the nearest millimeter, and reported in centimeters. Change is calculated separately for each segment as the postoperative distance minus its preoperative baseline value. Larger positive changes indicate greater swelling. |
| Secondary | Soft-tissue healing | Postoperative days 3 and 7 after each surgical procedure. | Healing of the soft tissue at the extraction site is assessed using the Landry healing index. The index evaluates tissue color, bleeding on palpation, granulation tissue, epithelialization of incision margins, and suppuration. Scores range from 1 (very poor healing) to 5 (excellent healing), with higher scores indicating better healing. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890272
GET https://conductscience.org/api/trials/v1/NCT07890272/registered